Cargando…

Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer

BACKGROUND: Radiation proctitis after intensity-modulated radiation therapy (IMRT) differs from that seen after pelvic irradiation in that this adverse event is a result of high-dose radiation to a very small area in the rectum. We evaluated the results of treatment for hemorrhagic proctitis after I...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Shinya, Shibamoto, Yuta, Ayakawa, Shiho, Nagai, Aiko, Hayashi, Akihiro, Ogino, Hiroyuki, Baba, Fumiya, Yanagi, Takeshi, Sugie, Chikao, Kataoka, Hiromi, Mimura, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403958/
https://www.ncbi.nlm.nih.gov/pubmed/22691293
http://dx.doi.org/10.1186/1748-717X-7-87
_version_ 1782238956419547136
author Takemoto, Shinya
Shibamoto, Yuta
Ayakawa, Shiho
Nagai, Aiko
Hayashi, Akihiro
Ogino, Hiroyuki
Baba, Fumiya
Yanagi, Takeshi
Sugie, Chikao
Kataoka, Hiromi
Mimura, Mikio
author_facet Takemoto, Shinya
Shibamoto, Yuta
Ayakawa, Shiho
Nagai, Aiko
Hayashi, Akihiro
Ogino, Hiroyuki
Baba, Fumiya
Yanagi, Takeshi
Sugie, Chikao
Kataoka, Hiromi
Mimura, Mikio
author_sort Takemoto, Shinya
collection PubMed
description BACKGROUND: Radiation proctitis after intensity-modulated radiation therapy (IMRT) differs from that seen after pelvic irradiation in that this adverse event is a result of high-dose radiation to a very small area in the rectum. We evaluated the results of treatment for hemorrhagic proctitis after IMRT for prostate cancer. METHODS: Between November 2004 and February 2010, 403 patients with prostate cancer were treated with IMRT at 2 institutions. Among these patients, 64 patients who developed late rectal bleeding were evaluated. Forty patients had received IMRT using a linear accelerator and 24 by tomotherapy. Their median age was 72 years. Each patient was assessed clinically and/or endoscopically. Depending on the severity, steroid suppositories or enemas were administered up to twice daily and Argon plasma coagulation (APC) was performed up to 3 times. Response to treatment was evaluated using the Rectal Bleeding Score (RBS), which is the sum of Frequency Score (graded from 1 to 3 by frequency of bleeding) and Amount Score (graded from 1 to 3 by amount of bleeding). Stoppage of bleeding over 3 months was scored as RBS 1. RESULTS: The median follow-up period for treatment of rectal bleeding was 35 months (range, 12–69 months). Grade of bleeding was 1 in 31 patients, 2 in 26, and 3 in 7. Nineteen of 45 patients (42%) observed without treatment showed improvement and bleeding stopped in 17 (38%), although mean RBS did not change significantly. Eighteen of 29 patients (62%) treated with steroid suppositories or enemas showed improvement (mean RBS, from 4.1 ± 1.0 to 3.0 ± 1.8, p = 0.003) and bleeding stopped in 9 (31%). One patient treated with steroid enema 0.5-2 times a day for 12 months developed septic shock and died of multiple organ failure. All 12 patients treated with APC showed improvement (mean RBS, 4.7 ± 1.2 to 2.3 ± 1.4, p < 0.001) and bleeding stopped in 5 (42%). CONCLUSIONS: After adequate periods of observation, steroid suppositories/enemas are expected to be effective. However, short duration of administration with appropriate dosage should be appropriate. Even when patients have no response to pharmacotherapy, APC is effective.
format Online
Article
Text
id pubmed-3403958
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34039582012-07-25 Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer Takemoto, Shinya Shibamoto, Yuta Ayakawa, Shiho Nagai, Aiko Hayashi, Akihiro Ogino, Hiroyuki Baba, Fumiya Yanagi, Takeshi Sugie, Chikao Kataoka, Hiromi Mimura, Mikio Radiat Oncol Research BACKGROUND: Radiation proctitis after intensity-modulated radiation therapy (IMRT) differs from that seen after pelvic irradiation in that this adverse event is a result of high-dose radiation to a very small area in the rectum. We evaluated the results of treatment for hemorrhagic proctitis after IMRT for prostate cancer. METHODS: Between November 2004 and February 2010, 403 patients with prostate cancer were treated with IMRT at 2 institutions. Among these patients, 64 patients who developed late rectal bleeding were evaluated. Forty patients had received IMRT using a linear accelerator and 24 by tomotherapy. Their median age was 72 years. Each patient was assessed clinically and/or endoscopically. Depending on the severity, steroid suppositories or enemas were administered up to twice daily and Argon plasma coagulation (APC) was performed up to 3 times. Response to treatment was evaluated using the Rectal Bleeding Score (RBS), which is the sum of Frequency Score (graded from 1 to 3 by frequency of bleeding) and Amount Score (graded from 1 to 3 by amount of bleeding). Stoppage of bleeding over 3 months was scored as RBS 1. RESULTS: The median follow-up period for treatment of rectal bleeding was 35 months (range, 12–69 months). Grade of bleeding was 1 in 31 patients, 2 in 26, and 3 in 7. Nineteen of 45 patients (42%) observed without treatment showed improvement and bleeding stopped in 17 (38%), although mean RBS did not change significantly. Eighteen of 29 patients (62%) treated with steroid suppositories or enemas showed improvement (mean RBS, from 4.1 ± 1.0 to 3.0 ± 1.8, p = 0.003) and bleeding stopped in 9 (31%). One patient treated with steroid enema 0.5-2 times a day for 12 months developed septic shock and died of multiple organ failure. All 12 patients treated with APC showed improvement (mean RBS, 4.7 ± 1.2 to 2.3 ± 1.4, p < 0.001) and bleeding stopped in 5 (42%). CONCLUSIONS: After adequate periods of observation, steroid suppositories/enemas are expected to be effective. However, short duration of administration with appropriate dosage should be appropriate. Even when patients have no response to pharmacotherapy, APC is effective. BioMed Central 2012-06-12 /pmc/articles/PMC3403958/ /pubmed/22691293 http://dx.doi.org/10.1186/1748-717X-7-87 Text en Copyright ©2012 Takemoto et al.;licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Takemoto, Shinya
Shibamoto, Yuta
Ayakawa, Shiho
Nagai, Aiko
Hayashi, Akihiro
Ogino, Hiroyuki
Baba, Fumiya
Yanagi, Takeshi
Sugie, Chikao
Kataoka, Hiromi
Mimura, Mikio
Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title_full Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title_fullStr Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title_full_unstemmed Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title_short Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
title_sort treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403958/
https://www.ncbi.nlm.nih.gov/pubmed/22691293
http://dx.doi.org/10.1186/1748-717X-7-87
work_keys_str_mv AT takemotoshinya treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT shibamotoyuta treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT ayakawashiho treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT nagaiaiko treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT hayashiakihiro treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT oginohiroyuki treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT babafumiya treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT yanagitakeshi treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT sugiechikao treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT kataokahiromi treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer
AT mimuramikio treatmentandprognosisofpatientswithlaterectalbleedingafterintensitymodulatedradiationtherapyforprostatecancer